<?xml version="1.0" encoding="UTF-8"?>
<supplementary-material content-type="local-data" id="MOESM1">
 <media xlink:href="12916_2020_1732_MOESM1_ESM.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">
  <caption>
   <p>
    <bold>Additional file 1: Appendix 1.</bold> Checklist summarising compliance with MOOSE and PRISMA guidelines. 
    <bold>Appendix 2.</bold> Details of search strategy. 
    <bold>Appendix 3.</bold> Details of clinical registry search strategy and data extraction. 
    <bold>Appendix 4.</bold> Studies included in systematic review. 
    <bold>Appendix 5.</bold> Country level data demonstrating number of treatment courses described in the literature, and date of first enrolment in prospective research, where relevant. 
    <bold>Appendix 6.</bold> Prisma flow diagram describing screening, eligibility and inclusion for clinical trial registration records for studies aimed at enrolling A(H1N1)pdm09 patients. 
    <bold>Appendix 7.</bold> Enrolment metrics for studies enrolling A(H1N1)pdm09patients, when analysis is restricted to ‘serious’ and hospitalized patients. 
    <bold>Appendix 8.</bold> Prisma flow diagram describing screening, eligibility and inclusion for clinical trial registration records for studies aimed at enrolling influenza patients, that were open during the pandemic period.
   </p>
  </caption>
 </media>
</supplementary-material>
